Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2010
01/19/2010US7649023 Using polyoxyethylene glycol solutions; mixing with drug
01/19/2010US7649021 Prostaglandin analog compositions to treat epithelial-related conditions
01/19/2010US7649020 treatment of sleep disorders and related diseases, with five novel polymorphic forms of modafinil racemate called CRL 40476 form III, CRL 40476 form IV, CRL 40476 form V, CRL 40476 form VI, CRL 40476 form VII; preparing a new solvate of modafinil comprising dissolving in solvent and crystallizing
01/19/2010US7649019 Modified release formulations of a bupropion salt
01/19/2010US7649017 Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same
01/19/2010US7649016 Comprising 1,5-D-anhydrofructose and/or ascopyrone; medicine has effects of ascopyrone in inhibiting the growth and metastasis of tumors, is expected to inhibit inflammation, and exerts an excellent effect on prognosis
01/19/2010US7649015 Saquinavir-like, a Lopinavir-like, a Ritonavir-like, a Indinavir-lik, a atazanavir-like, Nelfinavir-like.a Tipranavir-like, a Amprenavir-like, a KNI-like. a cyclic carbonyl-like phosphonate HIV protease inhibitors; drug designing
01/19/2010US7649014 Inhibit uncoupling protein-2 (UCP2); treating deficient first-phase insulin secretion, non-insulin dependent diabetes mellitus, and ischemia
01/19/2010US7649013 Administering to a subject in need thereof, prior to an exposure to radiation, a therapeutically effective amount of a modulator of cell cycle checkpoint activation, or a pharmaceutically acceptable salt, prodrug, metabolite, analog or derivative thereof, in particular, beta-lapachone
01/19/2010US7649012 Compounds, pharmaceutical compositions containing same, and methods of use for same
01/19/2010US7649011 Inhibitors of human tumor-expressed CCXCKR2
01/19/2010US7649010 Carvedilol hydrobromide
01/19/2010US7649009 N-(trans-4-tert-butylcyclohexyl)-1-{4-[(1h-tetrazol-5-ylamino)carbonyl]benzyl }-3-(3,4,5-trifluoropbenyl)-1h-pyrazole-5-carboxamide; type 2 diabetes, hyperglycemia, diabetes or insulin resistance, Syndrome X, atherosclerosis
01/19/2010US7649008 Crystal of 4-(1-((4-methylbenzothiophen-3-yl)methyl)benzimidazol-2-ylthio)butanoic acid; has chymase inhibitory activity in living body and can be used as a preventive and/or remedy for inflammatory diseases, allergic diseases, respiratory tract diseases, circulatory diseases, or bone metabolic diseases
01/19/2010US7649007 Oxazolidine derivatives as PR modulators
01/19/2010US7649006 Synthesis of epothilones, intermediates thereto and analogues thereof
01/19/2010US7649005 Substituted benzylaminoalkylene heterocycles
01/19/2010US7649004 Pyridine derivatives
01/19/2010US7649003 Substituted triazole derivatives as oxytocin antagonists
01/19/2010US7649002 (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
01/19/2010US7649001 Fused benzene derivative and use
01/19/2010US7649000 (2'S,2''R)-4-(2'-(2''-amino-3''-(4'''-ethoxyphenyl)propanoylamino)-3'-phenylpropanoyl-amino)piperidine- 1-carboxamidine; inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation
01/19/2010US7648999 Activator for peroxisome proliferator-activated receptor δ
01/19/2010US7648998 Imidazo 4,5-c pyridine compounds and methods of antiviral treatment
01/19/2010US7648997 Immunomodulators for inducing cytokine biosynthesis, for treatment of diseases including viral and neoplastic diseases; 1-[3-(Aminooxy)propyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine; N-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propoxy]cyclopropanecarboxamide
01/19/2010US7648996 39-desmethoxy derivatives of rapamycin
01/19/2010US7648995 R(—)-11-hydroxyaporphine derivatives and uses thereof
01/19/2010US7648994 Steroidal alkaloids that can be used in the treatment of hedgehog pathway related disorders, particularly cancer and psoriasis
01/19/2010US7648993 Metabotropic glutamate receptors 1 and 5 antagonists; (E)-6-methyl-2-styryl-pyridine, 6-methyl-2-(phenylazo)-3-pyridinol, alpha-methyl-4-carboxyphenylglycine and 2-methyl-6-(phenylethynyl)-pyridine; autism, fragile X syndrome; antiepileptic agents, anxiolytic agents
01/19/2010US7648992 Metalloproteinase 9 and/or 12 inhibitors; such as 5-({[4-[(2-cyclopropylpyrimidin-5-yl)ethynyl]-3,6-dihydropyridin-1(2H1)-yl]sulfonyl}methyl)-5-methylimidazolidine-2,4-dione; synthesis; asthma, chronic obstructive pulmonary disease
01/19/2010US7648991 Schizophrenia, psychoses, drug abuse, drug dependence, alcoholism; anxiolytic and antidepressant agents; psychological and bipolar disorders; crystallization, methylation, precipitation, separation
01/19/2010US7648990 Chemical compounds
01/19/2010US7648989 Indolylmaleimide derivatives as PKC inhibitors
01/19/2010US7648988 6-Chloro-2-piperazino-4-pyrrolidinopteridine derivatives; brain, nervous system, respiratory system, gastrointestinal, and psychological disorders; arthritis, antiasthmatics, cancer, leukemia, pain; Crohn's, Alzheimer's, and Parkinson's disease; multiple sclerosis; joint, eye and skin disorders
01/19/2010US7648987 Bicyclic protein kinase inhibitors
01/19/2010US7648986 Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine
01/19/2010US7648985 Oxabispidine compounds and their use in the treatment of cardiac arrhythmias
01/19/2010US7648984 Antibacterial agents
01/19/2010US7648983 Inhibits beta -secretase or beta -site amyloid precursor protein-cleaving enzyme (BACE); Alzheimer's disease; S)-4-(2,4-difluoro-5-(pyrimidin-5-yl)phenyl)-4-methyl-5,6-dihydro-4H-1,3-thiazin-2-amine
01/19/2010US7648982 Inhaling formulation providing analgesia to patient; contains one rapid-onset opioid and a sustained-effect opioid; avoiding toxicity while achieving analgesia, side effect occurs before the onset of toxicity; dispensers
01/19/2010US7648981 Opioid delivery system
01/19/2010US7648980 3-{2-[3-fluoro-6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-8-oxa-3-azabicyclo[3.2.1]oct-6-yl)amino]methyl}-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli
01/19/2010US7648979 5-amido-(1H-indol-2-yl)-piperazin-1-yl-methanone derivatives
01/19/2010US7648978 Modulates hepatocyte growth factor (HGF); fibrotic liver disease, hepatic ischemia-reperfusion injury, cerebral infarction, ischemic heart disease, renal disease or lung (pulmonary) fibrosis, multiple sclerosis; 4-[4-(1-homopiperidinyl)phenyl]-1-(2H)-phthalazinone
01/19/2010US7648977 Inhibits HIV-1(BaL) replication in Hut/CCR5 cells, HIV-1(IIIB) replication in GHOST/CXCR4 and normal human peripheral blood mononuclear cells (PBMC), and HIV-1 RT; antiviral agents; HIV
01/19/2010US7648975 Macrocyclic quinazoline derivatives as antiproliferative agents
01/19/2010US7648974 19-nor-vitamin D analogs with 3,2-dihydrofuran ring
01/19/2010US7648973 Metabolic bone disease; psoriasis; leukemia; colon, breast, prostate, skin, lung cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, asthma, psoriasis
01/19/2010US7648972 2-methylene-1α-hydroxy-19,21-dinorvitamin D3 analogs and uses thereof
01/19/2010US7648971 Thrombopoietin mimetics
01/19/2010US7648970 Delivering modified inositol hexaphosphate (IHP); enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells; cardiovascular and respiratory disorders
01/19/2010US7648968 Using water insoluble microparticulate glucans comprising branched beta -(1,3)(1,6) glucan, essentially free of unbranched beta -(1,3)(1,6) glucan and non-glucan components
01/19/2010US7648967 Using isoguanosine nucleoside analogs, and derivatives thereof, in cell cultures and in antiviral therapy; increasing the mutation rate of a virus such as bovine viral diarrhea virus and hepatitis C virus
01/19/2010US7648966 Mannose-6-phosphonate compounds for the treatment of inflammatory diseases
01/19/2010US7648959 Methods and compositions for the treatment of diseases of the eye
01/19/2010US7648957 Comprising a peptide fraction which is preferably rich in di- and tripeptides in combination with an insulin sensitizer, preferably a natural or pharmaceutical insulin sensitizer; suitable as pharmaceutical or food or a food supplement; especially useful for Type 2 diabetes
01/19/2010US7648828 Methods for detecting receptor complexes comprising PI3K
01/19/2010US7648826 Detecting CYP24 expression level as a marker for predisposition to cancer
01/19/2010US7648720 Dietary fiber delivery system
01/19/2010US7648714 Food for skin moisture retention
01/19/2010US7648712 Fast dissolving orally consumable films containing a taste masking agent
01/19/2010US7648711 Dimethicone-containing sustained release injection formulation
01/19/2010US7648710 Formulation containing phosphate derivatives of electron transfer agents
01/19/2010US7648706 West nile DNA vaccine
01/19/2010US7648705 Methods for prevention or amelioration of West Nile encephalitis using a West Nile DNA vaccine
01/19/2010US7648703 Combination of anti-EP-CAM antibody with a chemotherapeutic agent
01/19/2010US7648698 Vaccine for veterinary and human medicine prophylaxis and therapy
01/19/2010US7648696 Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent
01/19/2010US7648695 A halogenated xanthene derivative, preferably Rose Bengal; can be delivered at high concentrations to certain tissues
01/19/2010CA2671604A1 Medicament dosage for inhaler
01/19/2010CA2641571C Treatment of osteoarthritis
01/19/2010CA2551157C Novel kappa receptor selective opioid peptides
01/19/2010CA2544422C Soft steroid compositions for use in dry powder inhalers
01/19/2010CA2537103C Once daily dosage forms of trospium
01/19/2010CA2517001C Hemorrhoid treatment pad
01/19/2010CA2480783C An improved modified release preparation
01/19/2010CA2466869C Methods and compositions for ameliorating the undesirable effects of chemotherapy
01/19/2010CA2465928C Synthesis and purification of valacyclovir
01/19/2010CA2464243C Method and composition for dry eye treatment
01/19/2010CA2439268C Combination comprising a signal transduction inhibitor and an epothilone derivative
01/19/2010CA2427660C Biphenylcarboxamides useful as lipid lowering agents
01/19/2010CA2427177C Process for preparing distamycin derivatives
01/19/2010CA2420026C 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications
01/19/2010CA2418350C Oil/fat composition
01/19/2010CA2417971C Oil/fat composition
01/19/2010CA2413000C Five-membered ring compounds
01/19/2010CA2402751C Decahydro-isoquinolines
01/19/2010CA2393466C Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
01/19/2010CA2392361C Gastroretentive controlled release pharmaceutical dosage forms
01/19/2010CA2373255C Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
01/19/2010CA2373093C Methods and compounds for inhibiting amyloid deposits
01/19/2010CA2368097C Amide derivatives of 3,4-dihydroquinazolinone compounds useful as cytokine inhibitors
01/19/2010CA2366911C Compositions for improving fertility
01/19/2010CA2353805C Use of phytanic acid for the treatment of diabetes
01/19/2010CA2335107C Leptin-mediated gene-induction
01/19/2010CA2321547C Indole derivatives and medicinal compositions containing the same
01/19/2010CA2319640C Electrochemically reactive cathodes for an electrotransport device
01/19/2010CA2315897C Novel camptothecin tetracyclic analogues, preparation, methods, applications as medicines and pharmaceutical compositions containing them
01/19/2010CA2301891C Rna respiratory synctial virus vaccines
01/19/2010CA2239904C Inhibitors of interleukin-1.beta. converting enzyme